<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_nelfinavir.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:22:56 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Nelfinavir</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Paul A. Pham, Pharm.D. and John G. Bartlett, M.D.</author>
<br>
<span class="display_date">03-24-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>
<B>Available formulation in Zambia: Oral powder</B>: 50 mg/g. <B>Tablet:</B> 250 mg (as mesilate). </li>
<li>Not first-line PI due to lower potency vs.&nbsp;<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> and <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>. </li>
<li>Since absorption dependent on fatty food intake, suboptimal serum concentrations may be more common in resource-limited countries. </li>
<li>Extensive experience in pregnancy, but no longer recommended due to presence of ethyl methanesulfonate (a carcinogenic impurity found in nelfinavir). </li>
</ul>Zambia Information Author: Paul A. Pham, Pharm. D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar">INDICATIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>Treatment of HIV infection in combination with other antiretrovirals. </li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar">FORMS</h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top">
            <I>Viracept</I>
          </TD><TD valign="top">Nelfinavir (NFV)</TD><TD valign="top">Agouron (U.S. Canada) and Roche (outside the US and Canada) </TD><TD>oral</TD><TD>tablet</TD><TD>250 mg; 625 mg</TD><TD>$2.52 per 250 mg tablet; $6.30 per 625 mg tablet. </TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>oral</TD><TD>powder</TD><TD>50 mg/g (144 gm container)</TD><TD>$66.48</TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar">USUAL ADULT DOSING</h2>Pill burden:4 tabs/d (625 tab)<br>
<br>
<ul>
<li>With&nbsp;<A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> or <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>: standard doses</li>
<li>With <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>: NFV 1250 mg bid + <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> 1200 mg bid (limited data, not recommended).</li>
<li>With <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>: NFV 500-750 mg bid + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 400 mg bid (limited data, high rate of GI intolerance with marginal PK benefit, not recommended).</li>
<li>With <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>:NFV 1250 mg bid + <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> 1200 mg bid or NFV 750 mg tid + <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> 800 mg tid (not recommended)</li>
<li>With <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>: NFV 1250 mg bid + <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>&nbsp;600/150 mg (3 tabs) bid (no&nbsp;data; not recommended) </li>
<li>
<A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>&nbsp;,&nbsp;<A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A>, <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">TPV</A>, and <A class="headLines" target="_new" href="darunavir4a48.html?contentInstanceId=443123">DRV</A>: no data, avoid co-administration. </li>
<li>Not recommended with <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>.</li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar">RENAL DOSING</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>Usual dose. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>Usual dose likely (PK unchanged in renal failure). <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>Usual dose. Removed with HD, must be given post-HD on days of dialysis. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>No data: Usual dose likely. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>No data. <br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar">ADVERSE DRUG REACTIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">COMMON</span></td>
</tr>
</table>
<hr>
<ul>
<li>Self-limited secretory <A class="headLines" target="_new" href="../../diagnosis/organ_system/diarrhea8e47.html?contentInstanceId=432753">diarrhea</A> in 10-30%. Typically responds to regular use of fiber and calcium supplements, or loperamide.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lipodystrophy94a9.html?contentInstanceId=432804">Fat accumulation</A>&nbsp;</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/hyperlipidemia4edb.html?contentInstanceId=434827">Hyperlipidemia</A>&nbsp; </li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/diabetes_mellitus_and_insulin_resistance382a.html?contentInstanceId=432783">Insulin resistance</A>, +/- hyperglycemia or diabetes </li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/hepatotoxicity0e98.html?contentInstanceId=434823">Transaminase elevation</A>&nbsp; </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">RARE</span></td>
</tr>
</table>
<hr>
<ul>
<li>Urticaria (rare)</li>
<li>Severe hepatitis</li>
</ul>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar">DRUG INTERACTIONS</h2>Substrate of 2C19 (major) and CYP3A4 (minor), inducer and inhibitor at CYP 3A4, and inducer of glucuronosyl transferase. NFV active M8 metabolite is a substrate of CYP3A4 (major). Drugs that are inhibitors of CYP3A4 may increase levels of main NFV metabolite (N8). Drugs that are inducers of CYP2C19 may decrease NFV serum levels. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">Drug-to-Drug Interactions</span></td>
</tr>
</table>
<hr>
<a name="Drug-to-Drug Interaction"></a>
<h2 class="grayLineHeaderBar">Drug-to-Drug Interaction</h2>
<TABLE class="blueOutline" CELLPADDING="2" CELLSPACING="0"  BORDER="0">
<tr class="blueBarBG">
<td>Drug</td><td>Effect of Interaction</td><td>Recommendations/Comments</td>
</tr>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/azithromycin9ba3.html?contentInstanceId=441410">Azithromycin</A>
          </B></TD><TD valign="top">NFV not significantly affected. <A class="headLines" target="_new" href="../antimicrobial_agents/azithromycin9ba3.html?contentInstanceId=441410">Azithromcycin </A>AUC increased by 100%.</TD><TD valign="top">Monitor for <A class="headLines" target="_new" href="../antimicrobial_agents/azithromycin9ba3.html?contentInstanceId=441410">azithromcyin</A> adverse drug reaction (reversible ototoxicity and elevated LFTs).</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> AUC decreased by 42% and Cmin decreased by 52%. NFV AUC increased by 72%.</TD><TD valign="top">Avoid co-administration</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>
          </B></TD><TD valign="top">NFV AUC increased by 20%. <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> levels unchanged.</TD><TD valign="top">No significant drug interaction. Use standard doses of both drugs.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/fluconazoled462.html?contentInstanceId=434183">Fluconazole</A>
          </B></TD><TD valign="top">NFV AUC increased by 30%.</TD><TD valign="top">Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> AUC increased by 51%; NFV AUC increased by 83%.</TD><TD valign="top">Limited data for dosing <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> 1200 mg bid + NFV 1250 mg bid.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV</A> AUC decreased by 27%; NFV Cmin increased by 113%.</TD><TD valign="top">Avoid co-administration or Consider increasing <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> dose to 3 tabs bid with NFV co-administration (no data).</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>
          </B></TD><TD valign="top">No significant drug interaction</TD><TD valign="top">Use standard dose of both drugs.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin532e.html?contentInstanceId=434653">Rifampin</A>
          </B></TD><TD valign="top">NFV AUC decreased by 82%.</TD><TD valign="top">Co-administration not recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>
          </B></TD><TD valign="top">NFV AUC increased by 150%, Cmax by 95%. </TD><TD valign="top">Limited data: <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 400 mg bid and NFV 500 mg or 750 mg bid. Generally not combined since boosting with RTV will yield only minimal PK enhancement of NFV serum concentrations at the expense of GI intolerance.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQVsgc</A> AUC increased by 3-5 fold; NFV AUC increased by 18% and Cmax not altered</TD><TD valign="top">Dose NFV 1250 mg bid + <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV&nbsp;</A>1200 mg bid or NFV 750 mg tid + SQV 800 mg tid.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A>
          </B></TD><TD valign="top">APV increased 1.5-fold. </TD><TD valign="top">Insufficient data for dose recommendation. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Alprazolam
          </B></TD><TD valign="top">May increase serum levels of alprazolam</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider alternative benzodiazepine (i.e lorazepam, oxazepam, or temazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Amiodarone</B></TD><TD valign="top">May significantly increase amiodarone serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to case report of increased amiodarone levels with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> co-administration. <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>, APV, and <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>&nbsp;manufactors recommend against use of amiodarone, but all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the same potential of significantly increasing amiodarone serum levels. If co-administration can not be avoided, monitor for amiodarone ADR (PFTs and TSH). Consider monitoring serum levels of amiodarone, but its long half-life may make titration difficult.</TD>
</TR>
<TR>
<TD valign="top"><B>Amlodipine</B></TD><TD valign="top">May increase serum levels of amlodipine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging PR interval with Ca channel blocker co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>
            APV
          </B></TD><TD valign="top">APV clearance was decreased by 41%. NFV AUC increased by 15%.</TD><TD valign="top">Data based on PK modeling with many confounding variables (i.e <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> in background regimen). Consider NFV 1250&nbsp;mg bid + APV 1200&nbsp;mg bid or APV 800 mg tid + NFV 750 mg tid with TDM.</TD>
</TR>
<TR>
<TD valign="top"><B>Artemether (artemisinin)</B></TD><TD valign="top">May increase serum levels of artemether</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Close monitoring for artemether toxicity (bone marrow suppression, bradycardia, and seizure).</TD>
</TR>
<TR>
<TD valign="top"><B>Astemizole</B></TD><TD valign="top">May significantly increase astemizole serum levels</TD><TD valign="top">Contraindicated due to the potential for cardiac arrhythmias. Recommended alternative antihistamine: loratadine, fexofenadine, desloratidine, or cetirizine.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Atorvastatin
          </B></TD><TD valign="top">Atorvastatin AUC increased by 74%</TD><TD valign="top">Use with caution. Monitor for adverse effects (LFTs and CPK). Consider alternative agents: pravastatin, fluvastatin, or rosuvastatin. </TD>
</TR>
<TR>
<TD valign="top"><B>Azathioprine</B></TD><TD valign="top">Interaction unlikely</TD><TD valign="top">Applies to all PIs and NNRTI: Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Bepridil</B></TD><TD valign="top">May significantly increase bepridil serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. The manufacturer of <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>, <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>, and <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> does not recommend bepridil co-administration. This contraindication should extend to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> since a significant increase in bepridil serum level can result in pro-arrhythmic events such as VT, PVC, and VFib.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Bupropion
          </B></TD><TD valign="top">May increase bupropion serum levels slightly</TD><TD valign="top">Not likely to be clinically significant. Start with the lowest possible dose of bupropion. In a small case series no seizures reported with co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Carbamazepine</B></TD><TD valign="top">May significantly decrease serum levels of NFV</TD><TD valign="top">Consider alternative anticonvulsants (i.e valproic acid, lamotrigine, levetiracetam, or topiramate). Monitor carbamazepine levels and consider TDM of NFV.</TD>
</TR>
<TR>
<TD valign="top"><B>Caspofungin</B></TD><TD valign="top">Caspofungin serum levels were not affected. NFV not measured.</TD><TD valign="top">Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Chlordiazepoxide
          </B></TD><TD valign="top">May increase serum levels of chlordiazepoxide</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider alternative benzodiazepine (lorazepam, oxazepam, or temazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Cisapride</B></TD><TD valign="top">May significantly increase cisapride serum levels</TD><TD valign="top">Contraindicated due to potential for cardiac arrhythmias. Recommended alternative: metoclopramide.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Clorazepate
          </B></TD><TD valign="top">May increase serum levels of clorazepate</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider an alternative benzodiazepine (lorazepam, oxazepam, or temazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclophosphamide</B></TD><TD valign="top">May increase serum levels of cyclophosphamide</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> resulting in a 50% increase in cyclophosphamide serum levels. Since all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of increasing cyclophosphamide levels, close monitoring of cyclophosphamide induced toxicity is recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclosporine</B></TD><TD valign="top">May significantly increase serum levels of cyclosporine</TD><TD valign="top">Applies to all PIs: Monitor serum levels of cyclosporine closely with co-administration. Cyclosporine dose may need to be decreased.</TD>
</TR>
<TR>
<TD valign="top"><B>Depo-medroxyprogesterone acetate (DMPA) </B></TD><TD valign="top">NFV and M8 metabolite were not affected.DMPA levels were not reported.</TD><TD valign="top">No evidence of ovulation occurring based on progesterone levels through week 12. Use standard dose with co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Diltiazem</B></TD><TD valign="top">May increase serum levels of diltiazem</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging the PR interval with diltiazem co-administration. Diltiazem should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Disopyramide</B></TD><TD valign="top">May increase disopyramide serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Monitor disopyramide serum levels (target: 2 to 7.5 mcg/mL).</TD>
</TR>
<TR>
<TD valign="top"><B>Docetaxel</B></TD><TD valign="top">May increase serum levels of docetaxel</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Dofetilide</B></TD><TD valign="top">May significantly increase serum levels of dofetilide</TD><TD valign="top">No data. Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Use with caution. Monitor QTc closely and adjust dofetilide dosing based on QTc prolongation and renal function. Consider an alternative class III antiarrhythmic such as bretylium or ibutilide.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Dronabinol
          </B></TD><TD valign="top">No significant interaction.</TD><TD valign="top">Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Echinacea </B></TD><TD valign="top">May decrease NFV serum levels. Echinacea decreased CYP3A4 substrate (midazolam) by 23%</TD><TD valign="top">Clinical significance unknown but should be avoided with all PIs and NNRTIs until its safety is further evaluated.</TD>
</TR>
<TR>
<TD valign="top"><B>Ergot Alkaloid</B></TD><TD valign="top">May significantly increase serum levels of ergotamine resulting in acute ergot toxicity</TD><TD valign="top">Contraindicated. Consider alternative agent for migraine such as sumatriptan (but not eletriptan since it is a CYP3A4 substrate and significant drug-drug interaction occurred with CYP3A4 inhibitor).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Estazolam
          </B></TD><TD valign="top">May increase serum levels of estazolam</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider alternative benzodiazepines (lorazepam, oxazepam, or temazepam). </TD>
</TR>
<TR>
<TD valign="top"><B>Ethinyl estradiol and northindrone</B></TD><TD valign="top">Ethinyl estradiol AUC decreased by 47%, Northindrone decreased by 18%.</TD><TD valign="top">Advise pts to use additional or alternative method of contraception.</TD>
</TR>
<TR>
<TD valign="top"><B>Ethosuximide</B></TD><TD valign="top">May increase serum levels of ethosuximide</TD><TD valign="top">Applies to all PIs and<A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124"> DLV</A>: Consider switching to valproic acid for the treatment of absence seizure.</TD>
</TR>
<TR>
<TD valign="top"><B>Etoposide</B></TD><TD valign="top">May increase serum levels of etoposide</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Etravirine</B></TD><TD valign="top">NFV serum concentrations may be increased.</TD><TD valign="top">Consider usual dose, but no PK data. </TD>
</TR>
<TR>
<TD valign="top"><B>Felodipine</B></TD><TD valign="top">May increase serum levels of felodipine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging the PR interval with Ca channel blocker co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Fentanyl
          </B></TD><TD valign="top">May increase fentanyl serum levels</TD><TD valign="top">Use with caution. Consider morphine.</TD>
</TR>
<TR>
<TD valign="top"><B>Flecainide</B></TD><TD valign="top">May increase antiarrhythmic serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Avoid co-administration; if necessary, monitor flecainide trough levels with co-administration. Target: 200-1000 ng/mL. Toxicity is frequent with trough serum levels above 1000 ng/mL.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Flurazepam
          </B></TD><TD valign="top">May increase serum levels of flurazepam</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider alternative benzodiazepines (lorazepam, oxazepam, or temazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Fluticasone </B></TD><TD valign="top">Fluticasone may be significantly increased. </TD><TD valign="top">Avoid long term co-administration. Consider beclomethasone. </TD>
</TR>
<TR>
<TD valign="top"><B>Food&nbsp;</B></TD><TD valign="top">NFV AUC increased by 2-fold with 125 kcal with 20% fat meal. NFV AUC increased 5-fold 1000 kcal with 50% fatty meal.</TD><TD valign="top">NFV must be taken with a fatty meal (a minimum of 500 kcal with 20% fat).</TD>
</TR>
<TR>
<TD valign="top"><B>Garlic supplement </B></TD><TD valign="top">49% and 51% reduction of <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> Cmin and AUC, respectively.</TD><TD valign="top">Studies only done with <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>. Effect of garlic on the PK parameters of NFV is not known. Avoid co-administration with PIs and NNRTIs until it can be further studied. </TD>
</TR>
<TR>
<TD valign="top"><B>Granisetron</B></TD><TD valign="top">May increase serum levels of granisetron</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Due to the large therapeutic index of granisetron, potential interaction is unlikely to be clinically significant.</TD>
</TR>
<TR>
<TD valign="top"><B>Heroin (Diamorphine)</B></TD><TD valign="top">Drug interactions unlikely.</TD><TD valign="top">Applies to PIs and NNRTIs: interaction unlikely but illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Ifosphamide</B></TD><TD valign="top">May increase serum levels of ifosphamide</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of chemotherapy-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Irinoteacan</B></TD><TD valign="top">May increase irinoteacan serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Co-administration of <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> is contraindicated by manufacturer. All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> also have the potential for significant interaction with irinotecan, therefore the co-administration should be done with extreme caution.</TD>
</TR>
<TR>
<TD valign="top"><B>&nbsp;Itraconazole</B></TD><TD valign="top">CYP3A4 inhibitor and substrate -bidirectional inhibition with the potential to increase levels of itraconazole and co-administered PI. </TD><TD valign="top">No data with NFV. Standard dose NFV likely. Consider monitoring itraconazole with co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Ketoconazole
          </B></TD><TD valign="top">NFV AUC increased by 35%.</TD><TD valign="top">Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Lidocaine</B></TD><TD valign="top">May increase antiarrhythmic serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Use with caution, monitor lidocaine serum levels (target: 1.5 to 6 mcg/mL) with co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Lovastatin
          </B></TD><TD valign="top">May significantly increase lovastatin levels</TD><TD valign="top">Contraindicated. Recommended alternatives include pravastatin, rosuvastatin, and fluvastatin (and possibly atorvastatin - start with 10 mg/d and monitor for myopathy). </TD>
</TR>
<TR>
<TD valign="top"><B>
            Mefloquine
          </B></TD><TD valign="top">May increase serum levels of mefloquine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Consider monitoring mefloquine levels and mefloquine-induced toxicity (i.e dizziness, LFTs, and periodic ophthalmic examination).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Methadone
          </B></TD><TD valign="top">Decreased serum levels of inactive methadone (S)-isomer. No change in active methadone R-isomer.</TD><TD valign="top">Use standard dose. No withdrawal symptoms observed.</TD>
</TR>
<TR>
<TD valign="top"><B>Mexiletine</B></TD><TD valign="top">May increase antiarrhythmic serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Use with caution. Monitor EKG and serum levels. Serum levels exceeding 1.5 to 2 mcg/mL have been associated with an increased risk of toxicity.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Midazolam
          </B></TD><TD valign="top">May significantly increase midazolam levels</TD><TD valign="top">Do not co-administer. Consider alternative benzodiazepines (temazepam, oxazepam,or lorazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Milk thistle </B></TD><TD valign="top">Data limited to interaction study with milk thistle and <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>. IDV AUC: unchanged; IDV Cmin: decreased by 25%. </TD><TD valign="top">Clinical significance unknown. Unknown effect on the metabolism of other PIs or NNRTIs. Avoid co-administration with PIs and NNRTIs until it can be further evaluated. </TD>
</TR>
<TR>
<TD valign="top"><B>Mirtazapine</B></TD><TD valign="top">May increase serum levels of mirtazapine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with caution. Consider an alternative antidepressant (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine). </TD>
</TR>
<TR>
<TD valign="top"><B>MVC</B></TD><TD valign="top">May increase maraviroc's serum concentrations. </TD><TD valign="top">No data, but dose reduction of MVC to 150 mg BID should be considered.</TD>
</TR>
<TR>
<TD valign="top"><B>Mycophenolate (MMF)</B></TD><TD valign="top">NFV AUC decreased by 32%; NFV-M8 metabolite decreased by 32%.</TD><TD valign="top">Clinical significance unknown. Proper dosing has not been established. Consider an alternative boosted PI.</TD>
</TR>
<TR>
<TD valign="top"><B>Nefazodone</B></TD><TD valign="top">May increase serum levels of nefazodone</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with caution. Consider an alternative antidepressant (i.e SSRI: escitalopram, citalopram, sertraline, or fluoxetine). </TD>
</TR>
<TR>
<TD valign="top"><B>Nifedipine</B></TD><TD valign="top">May increase serum levels of nifedipine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging PR interval with Ca channel blocker co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Nisoldipine</B></TD><TD valign="top">May increase serum levels of nisoldipine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging PR interval with Ca channel blocker co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Paclitaxel
          </B></TD><TD valign="top">May increase paclitaxel serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Data limited to case reports of severe toxicity associated with <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> and <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> co-administration with paclitaxel. Since all PIs have the potential of significantly increasing paclitaxel serum levels, close monitoring of paclitaxel-induced toxicity is recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>PCP</B></TD><TD valign="top">May significantly increase serum levels of PCP</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>. Illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenobarbital</B></TD><TD valign="top">May significantly decrease serum levels of NFV</TD><TD valign="top">Consider alternative anticonvulsants (i.e valproic acid, lamotrigine, levetiracetam, or topiramate). Monitor phenobarbital levels and consider TDM of NFV.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenytoin</B></TD><TD valign="top">Phenytoin AUC decreased by 20-40%; No change in NFV AUC.</TD><TD valign="top">Monitor phenytoin levels, may need to increase phenytoin dose.</TD>
</TR>
<TR>
<TD valign="top"><B>Pimozide</B></TD><TD valign="top">May significantly increase pimozide serum levels resulting in QTc prolongation</TD><TD valign="top">Contraindicated. Consider alternative: Olanzapine.</TD>
</TR>
<TR>
<TD valign="top"><B>PPI </B></TD><TD valign="top">Nelfinavir and M8 metabolite AUC decreased by 36% and 92%, respectively. </TD><TD valign="top">Contraindicated. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Pravastatin
          </B></TD><TD valign="top">Pravastatin AUC decreased with co-administration.</TD><TD valign="top">Clinical significance unknown. May need to increase dose of pravastatin.</TD>
</TR>
<TR>
<TD valign="top"><B>Propafenone</B></TD><TD valign="top">May increase antiarrhythmic serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Co-administration should be avoided. Serum levels are not routinely recommended due to the poor correlation with efficacy and toxicity.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Quinidine
          </B></TD><TD valign="top">May increase antiarrhythmic serum levels</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Contraindicated with RTV. With all Ps and NNRTI co-administration, monitor EKG (QTc) and serum levels: Target: 2 to 5 mcg/mL.</TD>
</TR>
<TR>
<TD valign="top"><B>Raltegravir</B></TD><TD valign="top">NFV may induce raltegravir's metabolism. </TD><TD valign="top">RAL 400 mg twice daily currently recommended, but no PK data. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifabutin
          </B></TD><TD valign="top">NFV AUC decreased by 32%; Rifabutin levels increased by 207%.</TD><TD valign="top">If co-administration required, dose NFV to 1000 mg PO tid with rifabutin to 150 mg PO qd or 300 mg 3x/wk.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifapentine
          </B></TD><TD valign="top">NFV serum levels may be significantly decreased.</TD><TD valign="top">Avoid co-administration. Consider using rifabutin.</TD>
</TR>
<TR>
<TD valign="top"><B>Rosiglitazone</B></TD><TD valign="top">NFV AUC increased by 14% and Cmin increased by 18% (NS) (n="3).</TD><TD valign="top">No significant interaction. Use standard dose.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Rosuvastatin
          </B></TD><TD valign="top">Other CYP3A4 inhibitor (i.e <A class="headLines" target="_new" href="../antimicrobial_agents/erythromycin329b.html?contentInstanceId=434157">erythromycin</A>) did not affect rosuvastatin serum level.</TD><TD valign="top">Applies to PIs and NNRTI. In one study, rosuvastatin AUC and Cmax increased when co-administered with <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV</A>. Clinical significance unknown and no data available with other PIs and NNRTIs. Close monitoring recommended due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>Sildenafil</B></TD><TD valign="top">May increase sildenafil levels. No change in NFV serum levels.</TD><TD valign="top">Use with caution. Do not exceed 25 mg of sildenafil in 48hrs.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Simvastatin
          </B></TD><TD valign="top">Simvastatin AUC increased by 506%.</TD><TD valign="top">Contraindicated. Alternatives include pravastatin, fluvastatin, and atorvastatin (start with 10 mg/day). Monitor for ADRs due to limited clinical data.</TD>
</TR>
<TR>
<TD valign="top"><B>Sirolimus</B></TD><TD valign="top">Case report of sirolimus Cmin increased by 5-fold with NFV co-administration</TD><TD valign="top">Dose sirolimus based on serum levels. A significantly reduction of sirolimus dose with NFV co-administration is recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>St. John's wort</B></TD><TD valign="top">May significantly decrease NFV serum levels</TD><TD valign="top">Contraindicated. Studies done with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>&nbsp;and <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>&nbsp;but St John's wort may affect the metabolism of other PIs and NNRTIs. Use an alternative (more effective) antidepressant.</TD>
</TR>
<TR>
<TD valign="top"><B>Tacrolimus</B></TD><TD valign="top">Case report of increased tacrolimus serum levels with NFV co-administration.</TD><TD valign="top">Dose tacrolimus based on serum levels. A significantly reduction of tacrolimus dose with NFV co-administration is recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Tadalafil</B></TD><TD valign="top">May increase serum levels of tadalafil</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Start with 5 mg. Do not exceed 10 mg in 72 hrs. Consider sildenafil due to more clinical data and shorter half-life allowing for easier titration.</TD>
</TR>
<TR>
<TD valign="top"><B>Tamoxifen</B></TD><TD valign="top">May increase serum levels of tamoxifen</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of tamoxifen-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Teniposide</B></TD><TD valign="top">May increase serum levels of teniposide</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of teniposide-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Terfenadine</B></TD><TD valign="top">May significantly increase terfenadine serum levels</TD><TD valign="top">Contraindicated due to the potential for cardiac arrhythmias. Recommended alternative antihistamine: loratadine, fexofenadine, desloratidine, or cetirizine.</TD>
</TR>
<TR>
<TD valign="top"><B>THC</B></TD><TD valign="top">No interactions.</TD><TD valign="top">No drug interactions but illicit drug use should be avoided for obvious reasons.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Trazodone
          </B></TD><TD valign="top">May increase serum levels of trazodone</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Use with caution. Consider an alternative antidepressant (i.e. SSRI:escitalopram, citalopram, sertraline, or fluoxetine).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Triazolam
          </B></TD><TD valign="top">May significantly increase triazolam serum levels</TD><TD valign="top">Contraindicated. Consider alternative benzodiazepines(temazepam, oxazepam, or lorazepam).</TD>
</TR>
<TR>
<TD valign="top"><B>Vardenafil</B></TD><TD valign="top">May significantly increase serum levels of vardenafil</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: Do not exceed vardenafil 2.5 mg in 72hrs (with <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A>) or 2.5 mg in 24 hrs (with other PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>). Consider sildenafil due to more clinical data and less pronounced interaction. Avoid co-administration with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>.</TD>
</TR>
<TR>
<TD valign="top"><B>Verapamil</B></TD><TD valign="top">May increase serum levels of verapamil</TD><TD valign="top">Applies to all PIs and<A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124"> DLV</A>: Data limited to an interaction study conducted with <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> and diltiazem which resulted in doubling of diltiazem serum levels (this led to PR interval prolongation). All PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A> have the potential of prolonging the PR interval with Ca channel blockers co-administration. Ca channel blockers should be started with 50% of the dose and slowly titrated with close monitoring of BP and pulse.</TD>
</TR>
<TR>
<TD valign="top"><B>Vinblastine</B></TD><TD valign="top">May increase serum levels of vinblastine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of vinblastine-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Vincristine</B></TD><TD valign="top">May increase serum levels of vincristine</TD><TD valign="top">Applies to all PIs and <A class="headLines" target="_new" href="delavirdine3293.html?contentInstanceId=443124">DLV</A>: No data. Close monitoring of vincristine-induced toxicity recommended.</TD>
</TR>
<TR>
<TD valign="top"><B>Vitamin C </B></TD><TD valign="top">Data limited to interaction study with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> and vitamin C (1 g/d): IDV AUC decreased by 14% and Cmin by 32%. </TD><TD valign="top">Clinical significance unknown. Data not available for other PIs or NNRTIs. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Voriconazole
          </B></TD><TD valign="top">May decrease voriconazole AUC. Voriconazole may increase NFV levels.</TD><TD valign="top">Significant interaction with <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> and <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> (400 mg bid) but not <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>, data with other PIs and NNRTIs are not available and should be used with caution. In severe cases of invasive <A class="headLines" target="_new" href="../../pathogens/fungi/aspergillus_spp.35f5.html?contentInstanceId=432288">aspergillosis</A> where voriconazole is clearly the first line agent, the authors recommend close monitoring for therapeutic efficacy (+/- addition of another antifungal for aspergillosis i.e ambisome or caspofungin).</TD>
</TR>
<TR>
<TD valign="top"><B>Warfarin </B></TD><TD valign="top">Case report of increased INR when <BR>co-administered with <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>. </TD><TD valign="top">Other PIs and NNRTIs may affect warfarin requirements. Monitor INR closely. </TD>
</TR>
</TABLE>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar">RESISTANCE</h2>
<ul>
<li>D30N: most common primary mutation selected by NFV, resulting in intermediate resistance to NFV, but no cross-resistance to other PIs.</li>
<li>L90M: can also be selected by NFV, resulting in intermediate resistance to NFV and <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>, and low-level cross-resistance to other PIs.</li>
<li>Other PI mutations (L33F, 82A/F/T/S, 84V/A/C, 46I/L): multiple mutations will result in high-level resistance. </li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar">PHARMACOLOGY</h2>
<a name="N10F15"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">MECHANISM</span></td>
</tr>
</table>
<hr>Inhibition of HIV protease, which results in nonfunctional, immature and non-infectious virions.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                Variable absorption 20-80%; high fat food (20% and 50% fat content) increases absorption by 3-4 fold, respectively.</li>
<li>Metabolism and Excretion: 
                NFV is converted to its major active metabolite (M8) by CYP2C19; M8 is metabolized by CYP3A4. Both unchanged drug and metabolites are excreted in the feces.</li>
<li>Protein Binding: 
                99%.</li>
<li>Cmax, Cmin, and AUC: 
                Mean steady-state Cmax="3-4" mcg/mL; Cmin="1-3" mcg/mL; AUC = "53" mcg/mLhr.</li>
<li>T1/2: 
                3.5-5 hrs.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>Use with caution in ESLD.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>Category B: Placental passage unknown. Not teratogenic in rodent studies. Recent Roche NFV recall due to detection of ethyl methanesulfonate (EMS), a process-related impurity and human carcinogen, in NFV manufactured in Europe. This report prompted the FDA to recommend that HIV-infected pregnant women not be started on NFV and that those taking NFV be&nbsp;be switched from NFV to an alternative agent.<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>Unknown breast milk excretion. Breast feeding is not recommended in the U.S in order to avoid post-natal transmission of HIV to the child, who may not yet be infected.<a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar">COMMENTS</h2>
<ul>
<li>Pros: Extensive experience in pregnancy, but no longer recommended due to presence of ethyl methanesulfonate (a carcinogenic impurity found in nelfinavir); lack of PI cross-resistance with most failure (D30N mutation).</li>
<li>Cons: Unboostable PI; less potent than NNRTIs and boosted PIs; high variability in absorption with dependence on fatty foods; more <A class="headLines" target="_new" href="../../diagnosis/organ_system/diarrhea8e47.html?contentInstanceId=432753">diarrhea</A> compared to the other PIs; failure with L90M can occur (compared to little or no resistance with boosted PIs), leading to greater PI cross-resistance; bid dosing; recent finding of EMS in NFV, leading to FDA letter warning against used in pediatrics and pregnant women.</li>
</ul>
<a name="N10F5A"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>Rodriguez-French A, Boghossian J, Gray GE, et al.;
		The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.;        
		J Acquir Immune Defic Syndr;
		2004; Vol. 
		35; pp. 
		22-32;
		<br>ISSN:
	        	1525-4135;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=14707788&amp;dopt=abstract" target="_new">14707788</a>
<br>
<b>Comments:</b>Open-label, randomized study involving 249 naive pts with med CD4 212 and VL 4.83 log. Pts received <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> 1400 mg bid + <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> or NFV 1250 mg bid + <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A>/<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>. ITT analysis: VL &lt;50 through wk 48 in 55% of <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A>-treated pts vs. 41% of NFV-treated pts, difference of 14% (95% CI 2%, 27%). <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> retained good viral potency in pts with HIV RNA &gt;100,000 compared to NFV (55% vs. 24% achieved VL &lt;50, respectively). Mean VL comparable between treatment groups at wk 48: -2.41 log for <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> bid group and -2.32 log for NFV bid group. Mean treatment difference -0.082 (95% CI: -0.333 to 0.169). Only 24% of pts with VL &gt;100,000 achieved VL &lt;50 c/mL. &nbsp;<br>
<br>
</li>
<li>Rufo PA, Lin PW, Andrade A, et al.;
		Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signaling.;        
		Am J Physiol Cell Physiol;
		2004; Vol. 
		286; pp. 
		C998-C1008;
		<br>ISSN:
	        	0363-6143;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15075198&amp;dopt=abstract" target="_new">15075198</a>
<br>
<b>Comments:</b>Prospective study showing that NFV induces a secretory form of <A class="headLines" target="_new" href="../../diagnosis/organ_system/diarrhea8e47.html?contentInstanceId=432753">diarrhea</A> in HIV+ pts and has a secretagogue effect on intestinal epithelial cell lines. <br>
<br>
</li>
<li>Gathe JC, Ive P, Wood R, et al.;
		SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.;        
		AIDS;
		2004; Vol. 
		18; pp. 
		1529-37;
		<br>ISSN:
	        	0269-9370;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15238771&amp;dopt=abstract" target="_new">15238771</a>
<br>
<b>Comments:</b>Open-label, randomized study involving 649 naive pts with med. CD4 of 170 and VL of 4.81 log10.Pts received <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> 1400mg qd + RTV 200mg qd + <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A> 300mg bid + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> 150mg bid or NFV 1250mg bid + <A class="headLines" target="_new" href="abacavirc37e.html?contentInstanceId=432939">ABC</A> 300mg bid + <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> 150mg bid. ITT analysis: VL &lt;400 through wk 48 in 69% of <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> treated pts and 68% of NFV treated pts, difference of 1% (95% CI, -6%, 8%). VL &lt;50 through wk 48 in 55% of <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> treated pts vs. 53% of NFV treated pts. In a sub-analysis pts with VL &gt;100,000, both <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> and NFV (66% vs. 64%, respectively) achieved VL &lt;400. Daily <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV/r</A> was equivalent to NFV in PI-naive pts. Unfortunately, this study compared <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A> with NFV, a PI known to have an inferior PK profile compared to other agents in its class. <br>
<br>
</li>
<li>Robbins GK, De Gruttola V, Shafer RW, et al.;
		Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.;        
		N Engl J Med;
		2003; Vol. 
		349; pp. 
		2293-303;
		<br>ISSN:
	        	1533-4406;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=14668455&amp;dopt=abstract" target="_new">14668455</a>
<br>
<b>Comments:</b>ACTG 384: 620 pts randomized to compare sequential 3-drug regimens in 4 groups: <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>-based HAART combined with <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>&nbsp;/&nbsp;<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>&nbsp;or <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>&nbsp;/&nbsp;<A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A>&nbsp;or NFV plus <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>&nbsp;/&nbsp;<A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>&nbsp;or <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A>&nbsp;/&nbsp;<A class="headLines" target="_new" href="didanosine10dd.html?contentInstanceId=432941">ddI</A>&nbsp;. <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> outperformed NFV in all arms. Starting with a 3-drug regimen containing <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> combined with <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A>&nbsp;and <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A>&nbsp;appeared to delay failure of 2nd regimen, compared with starting a regimen containing NFV (hazard ratio for failure of 2nd regimen, 0.71; 95%CI, 0.48 to 1.06). <br>
<br>
</li>
<li>Walmsley S, Bernstein B, King M, et al.;
		Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.;        
		N Engl J Med;
		2002; Vol. 
		346; pp. 
		2039-46;
		<br>ISSN:
	        	1533-4406;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=12087139&amp;dopt=abstract" target="_new">12087139</a>
<br>
<b>Comments:</b>Prospective, double-blind trial involving 653 naive HIV+ pts. Pts randomized to <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> + <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A> / <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> or NFV + <A class="headLines" target="_new" href="stavudinec8c7.html?contentInstanceId=432952">d4T</A> / <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> . At wk 48, greater proportions of pts treated with <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> than of pts treated with NFV had VL&lt;400 (75% vs. 63%, P &lt;0.001) and &lt;50 (67% vs. 52%, P &lt;0.001). Less variability in response across VL and CD4 spectra with <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV/r</A> than NFV, and less resistance with failure. <br>
<br>
</li>
<li>Podzamczer D, Ferrer E, Consiglio E, et al.;
		A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).;        
		Antivir Ther;
		2002; Vol. 
		7; pp. 
		81-90;
		<br>ISSN:
	        	1359-6535;
	        <br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=12212928&amp;dopt=abstract" target="_new">12212928</a>
<br>
<b>Comments:</b>Prospective randomized trial comparing <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> / <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> / <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> to NFV/ <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> / <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> . At 12 mos in the ITT analysis, proportion of pts with VL &lt;200 was 60% in the NFV/ <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> / <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> arm and 75% <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> / <A class="headLines" target="_new" href="zidovudine08d0.html?contentInstanceId=432953">AZT</A> / <A class="headLines" target="_new" href="lamivudine495b.html?contentInstanceId=432946">3TC</A> arm (p=0.06),&nbsp;and proportion &lt;20 was 50% and 65%, respectively (p=0.06).&nbsp;Trend favoring <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> , but not statistically significant. <br>
<br>
</li>
</ol>
<a name="REFERENCED WITHIN THIS GUIDE"></a>
<h2 class="grayLineHeaderBar">REFERENCED WITHIN THIS GUIDE</h2>
<ul>
<li>
<A class="headLines" target="_new" href="didanosinef9df.html?contentInstanceId=432948&amp;siteId=429188">Didanosine</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/initial_regimen_for_arv_therapyf9df.html?contentInstanceId=432948&amp;siteId=429188">Initial Regimen for ARV Therapy</A>
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/organ_system/nausea_vomitingf9df.html?contentInstanceId=432948&amp;siteId=429188">Nausea/Vomiting</A>
</li>
<li>
<A class="headLines" target="_new" href="../../guidelines/zambia_hiv_national_guidelines/nutrition_care_and_supportf9df.html?contentInstanceId=432948&amp;siteId=429188">Nutrition Care and Support</A>
</li>
<li>
<A class="headLines" target="_new" href="../../management/antiretroviral_therapy/toxicity___side_effects__switching_therapy__zambia_specf9df.html?contentInstanceId=432948&amp;siteId=429188">Toxicity &amp; side effects: switching therapy (Zambia specific)</A>
</li>
</ul>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_nelfinavir.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:22:56 GMT -->
</html>
